Introduction
The third generation cephalosporins have been recommended by the WHO and CDC as first line drugs for the treatment of uncomplicated gonococcal infection. Unfortunately these antibiotics are frequently not available or are too expensive for STD patients in many countries. Resistance to cheaper alternatives such as trimethoprim-sulphamethoxazole and thiamphenicol has been detected in many developing countries; therefore, they cannot be recommended without first conducting a baseline assessment of their in vitro activity and in vivo efficacy.' In the early 1980s the oral second generation cephalosporin cefaclor was shown to be effective against gonococcal infection.2 4The antibiotic has the advantage of being administered as a single oral dose and has not been associated with any major side effects. Compared with the third generation cephalosporins, cefaclor also has the advantage of no longer being under patent and could therefore be marketed at a lower price. In the studies reported here we Reinfection was differentiated from treatment failure by the isolation of different gonococcal strains at the first and control visit by using serotyping and auxotyping methods previously described.5 6 If there was no difference and there was no history of re-exposure, the treatment was considered to have failed. Patients with microscopic evidence of gonorrhoea at the control visit were routinely administered oral ofloxacin 400 mg immediately plus doxycycline 100 mg twice daily for 7 days. Those with post-gonococcal urethritis received doxycycline only. All findings at the first and control visit were recorded on the case report forms. The trial was conducted in accordance with the Declaration of Helsinki and was approved by the ethics committees of One unexpected finding was the marked difference in MICs observed as a consequence of the methods used. The MICs recorded for the 171 isolates that were tested by both methods are shown in table 2. When using the DST method, all isolates except two had lower MICs than when the same isolates were tested with the NCCLS method. The MIC5o was 0.25 mg/l and the MICGo was 1 mg/l when using the DST method, while these values were 1 mg/l and 4 mg/l respectively when using the NCCLS method. The difference between the 171 pairs was highly significant (p < 0.001).
Discussion
The cure rate recorded for cefaclor in this open trial was 97%. This was similar to the results of other published efficacy studies conducted in the late 1970s and early 1980s, suggesting that cefaclor may be a valuable alternative for the treatment of uncomplicated urogenital gonorrhoea in countries with limited health resources, especially in a situation of growing resistance to the fluoroquinolones. 9 Panikabutra et al published a cure rate of 90% when cefaclor was administered as a 3 g single dose alone in Bangkok, Thailand, and of 96% when 3 g cefaclor and 1 g probenecid were administered jointly, although the difference between the two groups was not statistically significant. 2 Tupasi et al reported a 93% cure rate in 61 female patients with uncomplicated gonococcal infection who were given 3 g single dose with probenecid in Manila, Philippines.3 Finally, Spagna et al reported a cure rate of 98% in a study undertaken in Columbus, Ohio, but with a multiple dose treatment regimen. 4 Cefaclor and cefixime share the advantages of single oral administration, absence of toxicity in pregnancy, and lack of serious side effects. However, being a generic drug cefaclor could be marketed at a substantially lower price than cefixime.
Since cefaclor has no activity against either C trachomatis or the genital mycoplasmas the rate of PGU detected during this study (35%) is similar to rates previous recorded with single dose treatment using a lactam antibiotics. Under these circumstances the use of cefaclor in combination with multidose tetracycline/ doxycycline therapy would therefore be advocated in settings where syndromic management of acute urethritis is practised.
Nevertheless, the 30% rate of adverse effects reported in this trial is a matter for concern. There was no association between side effects and HIV status-testing had been carried out in these patients for another study protocol. Adverse effects were reported by 19 of the 50 HIV positive patients, and by 43 of the 122 HIV negative patients (p = 0.6). As anticipated, patients complained mainly of gastrointestinal symptoms. The six cefaclor and two probenecid tablets were administered with a single glass of water, and some patients had not eaten for several hours. The administration of cefaclor with food might lessen gastrointestinal effects, but food is also said to reduce the intestinal absorption rate and subsequently the maximum serum concentration. ' 
